RegenosineJersey City, New JerseyLife SciencesCohort: 2018-2019
Regenosine is developing a first-in-class disease modifying regenerative therapy for Osteoarthritis (OA). Their injectable slow-release adenosine formulation regenerates the articular cartilage and potentially delays the need for joint replacement procedures.
The startup represented here is a graduate of Endless Frontier Labs’ predecessor program, called Creative Destruction Lab-New York City, operated by NYU in partnership with University of Toronto during 2018-2019. The Endless Frontier Labs has no current engagement or affiliation with the Creative Destruction Lab.